Liraglutide and Cardio-Metabolic Risk Markers
- Conditions
- Type-2 Diabetes
- Registration Number
- NCT01715428
- Lead Sponsor
- University of Palermo
- Brief Summary
Incretin-based therapies have shown significant effects beyond those on glucose metabolism. We aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.
- Detailed Description
In details, we will evaluate the effects of liraglutide on carotid-intima media thickness, oxidative stress, ghrelin, heat shock proteins and lipoproteins.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
- patients with a diagnosis of type-2 diabetes
- severe hepatic or renal diseases
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method carotid intima-media thickness every four months for a total period of 2 years carotid intima-media thickness will be assessed by doppler ultrasonography
- Secondary Outcome Measures
Name Time Method changes in plasma ghrelin concentrations and heat-shock proteins after 2 months of therapy plasma ghrelin concentrations and heat shock protein 60 were measured by ELISA
changes in oxidative stress markers after 2 months of therapy Serum LOOH levels were evaluated following the oxidation of Fe2+ to Fe3+ in the presence of xylenol orange at 560 nm. Levels of GSH were measured in serum using a spectrophotometric assay based on the reaction of thiol groups with 2,2-dithio-bis-nitrobenzoic acid, while the production of ROS was assessed using fluorescent probe dihydroethidium staining (Sigma).
changes in atherogenic lipoproteins after 2 and after 4 months of therapy the full LDL subclass profile (from larger and less atherogenic LDL-1 and LDL-2, to smaller denser LDL-3 to LDL-7) was assessed by gel electrophoresis (Lipoprint, Quantimetrix, USA)
Trial Locations
- Locations (1)
University Hospital of Palermo
🇮🇹Palermo, Italy
University Hospital of Palermo🇮🇹Palermo, Italy